High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification

• DOI: 10.3389/fonc.2022.1070588
• Publication Date: 2023-01-16T05:13:20Z
• Authors: Xiaoyu Wang; Dan Liu; Erling Chen; Li Wang; Na Zhao; Li Zhou; Juan Tong; Lei Xue; Lei Zhang; Liangquan Geng; Baolin Tang; Huilan Liu; Xin Liu; Changcheng Zheng
• Keywords: Risk Stratification

Introduction We firstly investigate based on 2022 European Leukemia Net (ELN) risk stratification, whether standard-dose cytarabine multiagent sequential chemotherapy (SDMSC) is more beneficial than high-dose (HDAC) monotherapy in consolidation for the survival of adult acute myeloid leukemia (AML) patients. Methods One hundred and eighty-three AML patients with complete remission (CR) were evaluated. Results discussion The 3-year relapse rate was 33.4% HDAC group 50.5% SDMSC ( p =0.066). overall (OS) event-free (EFS) rates (69.2%, 60.7%) significantly higher that (50.8%, 42.1%) =0.025, 0.019). For intermediate group, OS EFS (72.5%, 56.7%) (49.1%, 38.0%) =0.028, 0.093). This study indicates young patients, achieves a long-term SDMSC, especially intermediate-risk according to ELN stratification.